PATIENT CONSENT FORM FOR COVID-19 TREATMENT

PURPOSE OF INFORMED CONSENT

As your physician has discussed with you, you have been diagnosed (or diagnosis is highly suspected) with novel COVID-19 (or SARS-CoV-2). At the current time, there are no FDA (Food and Drug Administration) approved, or clinically proven therapies for treatment of COVID-19. As clinical data emerges from other parts of the world, local treatment guidelines have been developed and will be updated as new information becomes available. Ventura County Medical Center (VCMC) and Santa Paula Hospital (SPH) guidelines reflect what is known about therapies that may work against the SARS-CoV-2 virus, have been used to treat other coronaviruses, or may theoretically target the underlying causes of virus-related severe lung conditions that make breathing difficult.

All therapies offered at VCMC & SPH for COVID-19 are considered "off-label", meaning they have been approved by the FDA to treat other diseases and conditions, but not COVID-19. Once a medication is approved by the FDA, the FDA depends on doctors to exercise professional judgment in prescribing that medication in a way that is beneficial to the patient. The FDA does not prohibit the use of medications in an "off-label" manner.

The following medications are being considered for off-label use in COVID-19:

Remdesivir	Tocilizumab
Dexamethasone	Other:

In order for you to be treated with the medication(s) listed above, you must sign this form to show that you agree to this off-label use and that you have been informed of the benefits and risks of taking such medications for off-label use, as well as the benefits and risks of declining or refusing such off-label use. You have the right to refuse to take this medication(s) for any reason.

The evidence at this time is not clear as to whether the proposed treatment will be beneficial. If you decline this off-label use of the recommended medication(s), you will still be provided all standard treatments but your condition may deteriorate despite use of standard treatments. Even with the recommended proposed off-label medication, your condition may deteriorate. However, due to the serious nature of COVID-19, no FDA approved medication, and no availability of clinical trials, an off-label medication is offered in the hope it could benefit you.

BACKGROUND

Remdesivir is an anti-viral medication that may help stop the virus from replicating in your body. Remdesivir was shown in a clinical trial to shorten the time to recovery in some people with COVID-19. The FDA has issued and Emergency Use Authorization (EUA) to permit the use of this unapproved medication in hospitalized patients with confirmed or suspected COVID-19. Clinical trials are ongoing to study its efficacy.

Dexamethasone is a corticosteroid medication that is used for a variety of conditions for its anti-inflammatory and immunosuppressant effects. It has been tested in clinical trials and found to may have benefit in those with COVID-19 pneumonia. Dexamethasone is not approved by the FDA for treatment of COVID-19.

Tocilizumab is an antibody (immune system protein) that blocks certain inflammatory processes in your body. By inhibiting or blocking these inflammatory processes, these medications may limit the damage COVID-19 causes to your lungs. Tocilizumab is an FDA- approved medication for the treatment of rheumatoid arthritis. It has not been approved by the FDA for the treatment of COVID-19.

PATIENT CONSENT FORM FOR COVID-19 TREATMENT

Page 1 of 3

VCHCA-800-037 (07/2020)



For other medications: list background rationale below or write "N/A":

DOSE AND ADMINISTRATION

Remdesivir --- 200mg intravenously on day one, followed by 100mg intravenously daily to complete five days total

Dexamethasone--- 6mg intravenously or orally, daily for 10 days

Tocilizumab – 400 mg intravenously for one dose

Other: _____

You will be monitored for improvement or worsening in COVID-19 symptoms, for any signs of new infections, and for signs of latent tuberculosis infection. It is anticipated that blood will be drawn on a daily basis to monitor your condition. Your liver function will be monitored at least weekly.

POSSIBLE BENEFITS

It is possible that the medications listed above may help to control your symptoms, slow or stop the growth of the virus, shorten the duration or lessen the severity of the illness in you. Possible benefits primarily include improvement in lung function (ability to breathe without assistance) and normalization of blood pressure.

However, given the off-label use of the medication(s) there is the possibility that these medications may be of NO direct medical benefit to you. Your condition may get worse.

POSSIBLE RISKS AND KNOWN SIDE EFFECTS

It is possible that the medication prescribed may not improve your symptoms and not shorten the duration nor severity of the illness. It is possible that the medication unexpectedly interferes with your ability to improve, hastens damage to the lungs or other organs, and shortens your life.

Remdesivir: There are limited clinical data available for remdesivir and unexpected adverse events may occur that have not been previously reported. Side effects of this may include increased liver function tests, in addition to nausea, vomiting, and low blood pressure during infusion.

Dexamethasone: Corticosteroids can result in elevated blood sugar, high blood pressure, water retention, difficulty sleeping. May also increase risk of other infections with bacteria, fungus, and reactivation of tuberculosis.

Tocilizumab: Many patients receive tocilizumab on a long-term basis for chronic conditions such as rheumatoid arthritis. As your physician is advising that you take only a single dose of this medication, side effects of a single dose of these medications are expected to be limited, but may include – injection site reactions, headache, high blood pressure, impaired liver function, reduced blood cell counts, perforation of the intestines and development of other infections including tuberculosis (TB) which may be serious or life-threatening.

Additionally, the FDA advises that testing for latent TB be conducted prior to administration of the medication and that if the test is

positive, that treatment for latent TB be initiated prior to administration of the medication. This is to prevent development of active TB. As your physician has discussed with you, due to the severity of your COVID-19 symptoms, by agreeing to this off-label use you agree to administration of tocilizumab prior to the availability of your test results for latent TB. You further agree and understand that should test results for latent TB turn out to be positive, treatment for TB will then be initiated after tocilizumab may have been administered.

Other: list side effects/risks below or write "N/A"

For more information about risks and side effects, please ask your physician. Please be advised that not all risks and side effects in the context of COVID-19 are known. Your physician may give you medication to help lessen the side effects. Some side effects are temporary. In some cases, side effects can be serious and can last a long time. Sometimes they never go away.

CERTIFICATION AND SIGNATURES

I have read this informed consent form and all of my questions have been asked and answered to my satisfaction by my physician. I understand that I have the right to refuse to take this medication(s) for any reason. If I choose not to take this medication(s), this decision will not otherwise affect my status as a patient. I voluntarily consent to take the medication(s) indicated on the first page of this document as discussed with my physician and as described in this consent form.

Name of Patient:				
Signature of Patient:		_ Date:	_Time:	
If patient is a minor; or is unable to sign, Indicate reason (ex: patient in COVID isolation):				
Name of Person Signing for the Patient:		-		
Signature of Person Signing for the Patient:		_Date:	_Time:	
Name of Witness:		-		
Signature of Witness:		_ Date:	_Time:	
Witness to complete for translation (if applicable):				
Translated by:	Language used:			
Relationship to Patient:		_ Date:	_Time:	

PATIENT CONSENT FORM FOR COVID-19 TREATMENT Page 3 of 3 VCHCA-800-037 (07/2020)